Benzinga | Aug 5, 2021 07:20AM EDT

Karyopharm Therapeutics Q2 EPS $(0.71) Beats $(0.74) Estimate, Net PRoduct Revenue $20.2M

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.74) by 4.05 percent. This is a 12.7 percent decrease over losses of $(0.63) per share from the same period last year.